NCT01418794

Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 606 (estimated)
• Sponsor: Shenyang Northern Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Polymer carried by drug-eluting stents may increase inflammatory response and thrombosis. Our previous study showed that polymer-free rapamycin-coated stents brings dose-dependent reduction in restenosis. This prospective, multicenter, randomized controlled clinical trials aimed to explore efficacy and safety of the YUKON drug eluting stent in diffuse coronary artery disease.

Conditions

• Acute Coronary Syndromes

Interventions

Type	Name	Description
DEVICE	High dose rapamycin stent	Concentration of rapamycin is 2.5%
DEVICE	Low dose rapamycin stent	Concentration of rapamycin is 1.5%

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-11-01
• First posted: 2011-08-17
• Last updated: 2011-08-17

Locations

4 sites across 1 country: China